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Abstract
Nigella sativa, commonly known as black seed, belongs to the botanical family of 
Ranunculaceae. Over recent years, there has been a growing interest in natural products 
including N. sativa due to their promising as anti-cancer effects. Several in vitro studies 
to determine the effect of N. sativa on the growth of the malignant melanoma cell line,
B16-BL6, and non-malignant cell lines were performed. We have shown that treatment of 
cells with a 70% ethanol extract of N. sativa can significantly inhibit proliferation of both 
malignant and non-malignant cells. Treatment with an aqueous extract of N. sativa can 
reduce the growth of malignant cell proliferation while having a lesser effect on non-
malignant cell proliferation. Ethanol extracts of N. sativa can induce apoptosis in treated 
B16-BL6 cells as confirmed using the Acridine Orange/Ethidium Bromide staining assay, 
Tunel assay, and Caspase activity assay. Some studies revealed that Thymoquinone is an 
important bioactive component of N. sativa and has anti-cancer effect. However, we aim 
to further investigate the active components of N. sativa using High-Performance Liquid 
Chromatography (HPLC) to identify the components that may be more effective in 
inhibiting cancer cell proliferation.
Keywords
Nigella sativa, B16-BL6 cells, Apoptosis, Caspases-2, Caspases-3, Caspases-6, Caspases-
8, Caspases-9.
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1Chapter 1: Literature Review
1.1. Melanoma
Cancer is the leading cause of death worldwide, and in Canada it is responsible
for about 30% of all deaths (Canadian Cancer Society, 2014). Among the different types
of skin cancer, melanoma is the third most common and the most aggressive form with
the highest mortality rate (Mandala, and Voit, 2013). In Canada, the rate of melanoma
incidence has been significantly increasing every year. Based on 2013 estimates, 6000
Canadians will be diagnosed with melanoma and 1050 will die from it, with higher
incidence in males than in females (Canadian Cancer Society, 2014). Melanoma has
become a cancer with a major socioeconomic impact due to its relatively high incidence
among young adults. Despite advances in cancer biology, malignant melanoma has a
poor prognosis with a median survival of less than or equal to one year with
chemotherapy (Garbe, and et al, 2011). Continuous efforts are being made to develop
better and more cost effective treatments with fewer side effects that could reduce the
incidence of the disease and improve the survival of cancer patients (Carocho and
Ferreira, 2013). Over recent years, there has been a growing interest in natural products
with anti-cancer properties as they are relatively cheap, and non-toxic with little or no
side effects.
Melanoma is a well characterized cancer, and it usually starts in the skin from the
malignant transformation of melanocytes – the cells that produce the pigment melanin
2which gives color to the skin (Canadian Cancer Society, 2014). The transformed
melanocytes proliferate uncontrollably and may begin to grow radially in the skin
resulting in an early stage melanoma that is characterized by the growth of tumors along
the dermo-epidermal junction (Uong and Zon, 2010). The radial growth may then be
followed by vertical growth (Uong and Zon, 2010). The melanoma may invade the
underlying dermis through the basement membrane and eventually metastasize (Uong
and Zon, 2010).
Several genes involved in melanocyte progress have been associated with the
initiation, progression and metastasis of melanoma (Uong and Zon, 2010). Genetic
research studies show that defects in tumor suppressor genes, aberrant activation of
receptor tyrosine kinases, mitogen activated protein kinases as well as variations and mis-
expression of G-protein coupled receptors are some of the processes involved in
malignant transformation of melanocytes (Wangari, et al, 2011). These genetic changes
can convert melanoma from a non –invasive form into an invasive tumor that is capable
of growing three-dimensionally and metastasizing (Wangari, et al, 2011).
Melanoma can affect any melanocyte-containing tissue including the skin, urinary
tracts uveal cutaneous tissue, oral mucosa, and nasopharynx (Wangari, et al, 2011). There
are three types of melanoma. Cutaneous melanoma is melanoma of the skin and is the
most common type (Melanoma Research Foundation, 2014). Another form of melanoma
that develop in any mucous membrane of the body such as the throat, nasal passages and
vagina and is called mucosal melanoma (Melanoma Research Foundation, 2014). Ocular
melanoma occurs in the eye and is a very unusual type (Melanoma Research Foundation,
2014).
31.2. Cell growth
Cell growth occurs through a series of highly regulated events that constitute the
cell cycle. The cell cycle is divided into two preparatory phases, G1 and G2, which are
required for the synthesis of cellular constituents needed to support the two functional
phases, S and M phase, in order to complete cell division (Andreeff, 2013). During G1,
rapid growth and metabolic activity occurs including RNA and protein synthesis
(Andreeff, 2013). The cell continues to grow during S phase, and DNA is replicated.
During G2 phase, the cell grows further and prepares for the M phase – Cell division. In
normal cells, transition from one phase to another is regulated by checkpoints (Andreeff,
2013).
The two broad classes of genes that encode proteins which help control cell
growth and proliferation are the tumor suppressor genes and the proto-oncogenes
(Hyland, 2014). Tumor suppressor genes inhibit cell growth or trigger apoptosis whereas
proto-oncogenes promote growth by encoding proteins that function as growth factors,
growth factor receptors, nuclear transcription factors, etc (Andreeff, 2013). The proto-
oncogene is usually mutated to form the oncogene which is always activated and results
in unregulated cell growth and transformation (Hyland, 2014). The most frequently
mutated gene in human cancer is the tumor suppressor p53 (Andreeff, 2013). Cells with
mutated p53 fail to arrest in G1 and do not undergo apoptosis, resulting in uncontrolled
cell growth and division leading to tumor development (Andreeff, 2013). In normal cells,
the tumor suppressor genes act as braking signals during G1 to stop or slow down the
cell’s entry into the S phase. For example, the tumor suppressor p53 positively regulates
the S phase checkpoint as shown in figure 1:1 (Ruddon, 2003). P53 is activated in
4response to DNA damage, resulting in either G1 cell cycle arrest or apoptosis (Ruddon,
2003). In a similar manner, the Ras and Myc oncogenes act to inhibit the G1 and G2
phase checkpoints (Chow, 2010).
Unlike normal cells, cancer cells can proceed through these cell cycle checkpoints
and can continue to replicate the damaged DNA thus accumulating mutations (Ruddon,
2003). Both copies of a tumor suppressor gene must be mutated for cancer to occur
whereas only one mutated allele is sufficient to convert a proto-oncogene into an
oncogene (Ruddon, 2003). Cells with mutated proto-oncogenes and tumor suppressor
genes do not recognize cell signals and continue to grow and divide uncontrollably
forming tumors. Genetic mutations could be the result of environmental factors or could
be inherited.
5Figure 1.1. Cell cycle control by tumor suppressors and oncogenes (taken 
from Ruddon, 2003) <http://www.ncbi.nlm.nih.gov/books/NBK12516/>
1.3. Causes of melanoma
Melanomas like all cancers are caused by the accumulation of mutations in genes
whose products directly regulate cell proliferation, apoptosis and DNA repair- (tumor
6suppressor, proto-oncogenes and DNA repair genes) (Hyland, 2014).
Disruption in the balance between cell proliferation and cell death results in the loss of
the ability to undergo apoptosis and/or leads to uncontrollable cell growth and cancer.
The global incidence of melanoma continues to rise. Several factors are associated
with melanoma risk. However, the most important risk factors that predispose to the
development of melanoma are exposure to the sun and ultraviolet radiation (UVR)
(Canadian Cancer Society., 2014). UVR damages DNA through the formation of
photoproducts and reactive oxygen species (ROS) (Grimaldi, et al., 2014). The risk
increases with intermittent exposure and from exposure early in life (childhood and
adolescence) (Armstrong, 1997). Among the three types of UVR, UVB is the most
strongly associated with melanoma development. Tanning beds and sunlamps are another
source of UVR and may increase the risk of melanoma (The Skin Cancer Foundation,
2014).
The risk of developing melanoma increases with the number, type, and size of
common or atypical/dysplastic nevi (moles) (Mandala and Voit, 2013). Moreover, people
with very large congenital melanocytic nevi are at a higher risk than those with small
nevi (Canadian Cancer Society, 2014). Individuals with Familial atypical multiple mole
melanoma (FAMMM) syndrome are also at a greater risk for melanoma. (Canadian
Cancer Society, 2014).
Another risk factor is skin colour. The risk of melanoma is much higher in light
skinned people as they have less melanin to protect them from UVR exposure (Canadian
Cancer Society., 2014).
A number of gene mutations have been associated with the familial melanoma 
7that accounts for approximately 10% of all melanoma cases (Marzuka, et al, 2014). 
Mutations in these genes can result in uncontrolled cell growth and cancer. These 
melanoma susceptibility genes include; BRAF, p53, BAPT, and CDKN2A (cyclin-
dependent kinase inhibitor 2A) (The Skin Cancer Foundation., 2014).The most common 
susceptibility gene is the CDKN2A locus and its mutated form shows an impaired 
capacity to inhibit the cyclin D1-CDK4 complex that allows for unchecked cell cycle 
progression (Marzuka, et al, 2014). Approximately 50% of all melanomas have 
oncogenic BRAF mutations, 90% of which are BRAFV600E (Box, et al, 2014). P53, the 
tumor suppressor gene that triggers cell death has also been shown to be inactivated in 
most melanomas (Box, et al, 2014). Mutations in the tumor suppressor BAP1 have also 
been shown to enhance the metastatic potential of certain types of melanomas (Marzuka, 
et al, 2014). Hence, the transformation of melanocytes into melanoma involves the 
interplay between some genetic factors, the tumor microenvironment, and UV exposure
(Grimaldi, et al., 2014).
1.4. Apoptosis
Apoptosis is a form of programmed cell death that involves a series of genetically 
controlled events to eliminate old, damaged or unwanted cells from the body (Fernald
and kurokawa, 2013). Apoptosis takes place via two major pathways: the extrinsic 
pathway, that involves death receptors; or the intrinsic pathway, that is linked to 
mitochondrial functions (Attoub, et al, 2013) as shown in figure 2 and figure 3. Both 
pathways consist of three stages: the induction phase (detection of damage signals); the 
8commitment phase (damage signals are integrated and modulated by pro or anti-apoptotic 
factors and initiator caspases which are caspase-2,-8,-9 or -10); and, the degradation 
phase (involves the activation of executioner caspases [e.g caspase -3 or -7] which 
degrade the matrix and cytoskeleton; and endonucleases which cleave DNA) (Attoub, et 
al, 2013).
The extrinsic pathway is initiated by extracellular ligands such as Fas and Tumor
necrosis factor (TNF) binding to several types of death receptors, leading to the formation
of the death-inducing signaling complex (DISC) which activates the initiator capases,
caspase-8 and caspase-10 (Riedl, and Salvesen, 2007; Fernald and kurokawa, 2013).
The intrinsic pathway involves the mitochondrial outer membrane permeabilization
(MOMP) (Riedl, and Salvesen, 2007; Fernald, and kurokawa, 2013). MOMP triggers the
release of pro-apoptotic mediators, apoptosis-inducing factor (AIF), heat-inducible serine
protease HTR-A2 and cytochrome c in response to specific signals (Fernald, and
kurokawa, 2013). The release of cytochrome c from the inter membrane space of the
mitochondria leads to the assembly of a signaling platform, the apoptosome, which
activates caspase-3/7 and leads to the cleavage of PARP (Poly ADP-ribose polymerase)
and the death response (Attoub, et al, 2013; Gurung, et al, 2010; Riedl, and Salvesen,
2007). The Bcl-2 superfamily consisting of both pro- and anti-apoptotic members plays a
major role in regulating apoptosis by interacting with MOMP at the mitochondria
membrane (Fernald, and kurokawa, 2013).
Apoptosis is triggered in response to internal and external stimuli. Any disruption
of the apoptotic process leads to abnormal cell growth and potential tumor development.
Cancer cells have the ability to evade apoptosis by changing the function or expression of
9anti- or pro-apoptotic proteins transcritptionally, translationally and post-translationally
(Fernald, and kurokawa, 2013). Like any other cancer cell, melanoma cells also escape
cell death by inactivating many sensors, regulators and effectors of the apoptotic and non-
apoptotic pathways (Soengas and Lowe, 2003).
Cell death control during melanoma progression has been associated with three
types of molecular changes: activation of anti-apoptotic factors; inactivation of pro-
apototic effectors; and, reinforcement of survival signals (Soengas, and Lowe, 2003).
Anti-apoptotic factors such as two members of the IAP family (surviving and ML-IAP)
and FLIP are shown to be over expressed in invasive and metastatic melanoma (Irmler, et
al, 1997; Grossman, and Altieri, 2001) Survival signaling in melanoma can be derived
from the activation of the P13K/AKT/PTEN, the NF-KB and the Raf/MAPK pathways
(Soengas and Lowe, 2003).
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Figure 1.2. Apoptosis (taken from Riedl, and Salvesen, 2007)
<http://www.nature.com/nrm/journal/v8/n5/full/nrm2153.html>
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Figure 1.3. Simplified schematic of apoptotic pathways in mammalian
cells:
(Death receptor-mediated) and intrinsic (mitochondrial) apoptosis (left panel). 
“Examples of upregulated and downregulated apoptotic factors in melanoma are 
indicated on the right panel” (taken from Soengas, and Lowe, 2003)
<http://www.nature.com/onc/journal/v22/n20/full/1206454a.html>
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1.5. Melanoma Treatment
The treatment for cancer depends on factors including the age and medical status of
the patient, the extent and site of the disease, rate of disease progression, available
treatments and the patients’ wishes. Early Melanoma that is confined to the primary site
is initially managed with surgical excision, with or without adjuvant chemotherapy and
radiotherapy (Govindarajan, et al, 2003).
The three most common FDA- approved drugs that have been in use for the
treatment of metastatic melanoma are dacarbazine, hydroxyurea and interleukin-2 (IL-2)
even though response rates have been low and the overall survival results have been
disappointing (Gogas, et al, 2013).
Dacarbazine is still considered as the standard treatment in Europe. Recent phase
III clinical trials show low response rates between 6.8-13.8% and median progression-
free survival between 1.5 and 2.9 months (Perrin, et al., 2014).
Currently, Hydroxyurea (HU) is used as a cancer chemotherapeutic agent which acts
specifically on the S-phase of the cell cycle (Madaan, et al, 2012). HU is shown to inhibit
the enzyme ribonucleoside diphosphate reductase thereby hindering the conversion of
ribonucleotides to deoxyribonucleotides and as a result limiting new DNA synthesis
(Madaan, et al, 2012).
IL-2 plays a central role in immune regulation as a T-cell growth factor (Gogas, et
al, 2013). Administration of high doses of IL-2 has shown dose-dependent anti-tumor
effects in phase II studies, although its effect has not been tested in phase III trials
(Gogas, et al, 2013). Administration of IL-2 requires hospitalization due to its severe
13
toxic side effects (Gogas, et al., 2013). Moreover, the high costs associated with it did not
allow extensive use in the community and it is not generally approved in the European
countries (Gogas, et al, 2013). Surgery, chemotherapy and radiotherapy are the traditional
therapies that have been shown to control local diseases in selected patients but have not
had a significant impact on the survival of patients with advanced and metastatic
melanoma (Wangari, et al, 2011). In fact, patients diagnosed with metastatic melanoma
have a high mortality rate due to the resistance of most melanomas to chemotherapeutic
drugs. Therefore, new and more effective therapies for melanoma are on-going.
Immunotherapy and molecular targeted therapy hold great promise.
1.6. Immunotherapy
Immunotherapy is another form of cancer treatment that works by stimulating the
body’s own immune system to attack melanoma cells more effectively (American Cancer
Society, 2013). It includes adoptive T cell therapy and vaccination. The main type of
immunotherapy being used to treat some forms of advanced melanomas include the use
of monoclonal antibodies targeted against immunosuppressive molecules such as
CTLA4, PD-1 and PD-L1. One such monoclonal antibody called Ipilimumab or Yervoy
is targeted against the cytotoxic T lymphocyte antigen-4 (CTLA4) which is expressed by
T regulatory cells. (Wangari, et al, 2011). Ipilimumab works by blocking the CTLA-4
inhibitory signal allowing cytotoxic T lymphocytes (CTL) to destroy tumor cells (Ribas,
2012). It has been shown to increase overall survival by 2 years in patients with advanced
melanoma (Weber, et al, 2009). Ipilimumab was approved in 2011 by the U.S. FDA for
14
the treatment of melanoma (Mandala, and Voit, 2013). Tremelimumab is another anti-
CTLA 4 monoclonal antibody which is being used to treat patients with metastatic
melanoma (Gogas, et al, 2013).
Another potential target molecule for immunotherapy of human melanoma is
HER2. HER2 is a glycoprotein belonging to the family of epidermal growth factor
receptor with intrinsic tyrosine kinase activity (Ma, et al, 2013). The use of Herceptin, a
humanized monoclonal antibody has been proven to be an effective treatment in breast
cancer patients with HER2 overexpression (Ma, et al, 2013). Herceptin binds to the
extracellular, juxtamembrane domain of HER2. HER2 overexpression has also been
demonstrated in patients with metastatic melanoma and therefore suggests the potential
role of Herceptin in the treatment of melanoma (Ma, et al, 2013).
Melanoma vaccines are still being studied in clinical trials (American Cancer
Sociey, 2014). However, sometimes to treat stage 3 melanomas, the Bacille Calmette-
Guerin (BCG) vaccine is used by injecting it directly into tumors (American Cancer
Sociey, 2013). BCG is a potent activator of the immune system which works by
activating an immune response near the site of injection (American Cancer Sociey, 2013).
1.7. Molecular targeted therapy
Melanoma is usually resistant to cytotoxic chemotherapy therefore systemic
therapies have been largely ineffective. In recent years, advanced understanding of the
causing genetic events that cause melanoma has led to the development of new targeted
drug therapies. Molecular studies show that most melanomas contain mutations,
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particularly amine acid substitutions, in the serine-threonine kinase BRAF (Patol, 2013)
as well as in the mitogen-activated protein kinase (MAPK) pathway (Johnson, and
Sosman, 2013). Vemurafenib, Dabrafenib and Trametinib are three drugs that act against
the altered BRAF gene (Canadian Cancer Society, 2014). These drugs have showed
better rates of progression-free and overall survival in patients with advanced melanoma
when compared to chemotherapeutic drugs including dacarbazine (Canadian Cancer
Society, 2014).
Vemurafenib was approved in 2011 for the treatment of metastatic melanoma
(Gogas, et al, 2013). It is a small tyrosine inhibitor that has been shown to promote
complete or partial tumor regression with a median PFS (Progression Free Survival) of 7
months (Bollag, et al, 2014). Vemurafenib and Dabrafenib, the two BRAF inhibitors and
Trametinib, a MEK inhibitor have all shown their effectiveness by increasing overall
survival in phase III trials for patients with BRAF-mutant melanomas (Mandala, and
Voit, 2013).
Additionally, imatinib is another promising targeted therapy for patients with
KIT-mutant melanoma (Johnson and Sosman, 2013). Two phase II trials have been
completed which demonstrate the activity of imatinib in patients with KIT mutant
melanoma (Johnson and Sosman, 2013). In the first trial, 28 patients with KIT mutations
were treated with imatinib and showed a durable response rate of 16%, a median
progression-free survival of 12 weeks and 72% of the patients had at least temporary
disease stabilization (Johnson and Sosman, 2013; Carvajal, et al, 2011). Whereas in the
second trial, 43 patients with KIT aberrations showed a 23% response rate, an additional
30% of the patients showed temporary disease stabilization, and the median progression-
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free survival was 3.5 months (Guo, et al, 2011; Johnson, and Sosman, 2013). Mucosal
and acral melanomas often have mutations in the KIT receptor and could be treated with
imatinib (Patol, 2013). The difficulty with these new treatments is that they are very
responsive and are associated with significant side effects in the treated patients.
1.8. Introduction to Natural Products
The incidence of melanoma is increasing worldwide. The early stage melanoma is
confined to epidermis and is curable through surgical excision (Looi, et al, 2013;
Govindarajan, et al, 2003). However, the prognosis decreases with increased thickness of
the lesions mainly due to the tendency of melanoma to metastasize (Govindarajan, et al,
2003). Moreover, melanomas are characterized to be highly resistant to most forms of
chemotherapy which contributes to high morbidity and mortality rates in patients
(Govindarajan, et al, 2003). The poor prognosis for metastatic melanoma, due to lack of
effective treatments, prompts the need for compounds with greater anti-melanoma
activity. Experimental studies show that many natural products and plant extracts have
anticancer potential in a variety of bioassay systems and animal models (Abukhader,
2013).
A natural product (NP) is a chemical substance or group of substances produced
by a living organism that are used without chemical modification or treatment. Natural
Products including medicinal plants have been used for treatment and prevention of
diseases for many centuries. Among the various medicinal plants, Negilla sativa, an
oriental spice, has been widely used in herbal medicine due to its wide spectrum of
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pharmacological actions (Ahmad, et al 2013). In Islamic literature, it is considered to be
one of the greatest forms of healing medicine and is referred to as the miracle herb
(Ahmad, et al 2013). The seeds of the plant have been used to prevent and cure disease
for centuries especially in the Middle East and Southeast Asia (Gilani, et al, 2004).
Recently this herb has shown encouraging potential as an anticancer agent.
1.9. Nigella Sativa
N. Sativa, popularly known as black seed, is an annual flowering plant that
originated from southeastern Asia (Khan, et al, 2011; Ahmad, et al 2013). The plant,
belongs to the botanical family Ranunculaceae (A), and is widely grown in different parts
of the world, most commonly in Eastern Europe, the Middle East and Western Asia
(Randhawa, and Alghamdi, 2011).
N. sativa grows up to 30 cm in height with linear leaves that are finely divided.
The flowers are usually blue and white, without involucres (Figure 1.4). The fruits are
large inflated capsules composed of 3-7 united follicles which contain the seeds. The
seeds (Figure 1.5) produced are small dicotyledons, black externally with an aromatic
odor and bitter taste (Ahmad, et al 2013).
18
Figure 1.4. Nigella Sativa Flower Figure1.5. Nigella Sativa Seeds
Source: http://en.wikipedia.org/wiki/File:Nsativa001Wien.jpg
http://en.wikipedia.org/wiki/File:Nigella_Sativa_Seed.jpg
The seeds are extensively used as a spice for nutritional flavorings such as in
breads, soups, pickles, sauces, etc (Khan et al, 2011). It is also used in cosmetics and
externally on the skin (Hajhashemi, et al, 2004). Raw seeds as well as the seed oil of N.
sativa has been widely used all over the world in traditional medicine for the treatment of
various illnesses including bronchitis, rheumatism, diarrhea, headache, hypertension,
gastrointestinal problems and eczema (Ahmad, et al 2013; Woo, et al, 2012).
In recent years, extensive research on N.sativa shows that it possess a variety of
phytochemical and pharmacological effects including antidiabetic, anticancer, analgesic,
antimicrobial, bronchodilator, anti-inflammatory and antioxidant properties (Ahmad, et
al, 2013). The chemical composition of black seeds has been characterized using a
variety of analytical and spectroscopic techniques and has been shown to contain both
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fixed and essential oils,15 amino acids, proteins, carbohydrates, alkaloids, saponins (Ali,
and Blunden, 2003) as well as minerals including calcium, iron, sodium and potassium
(Gali-Muhtasib, et al, 2006). The identified bioactive components of black seeds include
thymoquinone, thymol, thymohydroquinone and dithymoquinone (Attoub, et al, 2013).
However, the most important active component of black seeds is thymoquinone (TQ)
found in the essential oils (Ahmad, et al., 2013).
1.10. Thymoquinone
Thymoquinone (TQ) is the major bioactive component of the volatile oils of black
seed, N. sativa (Attoub, et al, 2013). The chemical structure of TQ is shown in (Figure
1.6).
Figure 1.6. Chemical structure of thymoquinone
Cell Biology International. Portland Press limited. Web. 23 April 2014.
Source: http://www.cellbiolint.org/cbi/035/1025/cbi0351025f05.gif
20
TQ has been shown to exert anti-oxidant (Khan et al, 2011), anti-inflammatory
and antineoplastic effects both in vitro and in vivo (Gali-Muhtasib, et al, 2006; Woo, et
al, 2012). Studies show that of TQ is effective against various diseases like cancer,
diabetes, asthma and kidney diseases etc (Khan, et al, 2011).
1.11. Black seed and cancer
Extensive research studies have investigated the wide spectrum of
pharmacological actions of N.sativa including its antibacterial, antifungal, antioxidant,
antidiabetic and anticancer activity (Ahmad, et al, 2013). TQ is the most abundant
bioactive constituent of black seed identified so far and a major anticancer agent (Attoub,
et al, 2013) with a low general toxicity (Effenberger and Schobert, 2011).
1.12. Thymoquinone’s potential role as an anticancer agent
Scientific studies have revealed the potential of TQ as an anticancer agent.
Evidence comes from several experimental findings that demonstrate the promising role
of TQ on a variety of tumor cells including human colon, breast, brain, melanoma,
pancreatic and ovarian cells (Gali-Muhtasib, et al, 2006; Gurung, et al, 2010; Rooney,
and Ryan, 2005; Woo, et al, 2012).
Attoub et al (2013) examined the effect of increasing TQ concentrations on cells
derived from lung (LNM35), liver (HepG2), colon (HT29), melanoma (MDA-MB-435),
and breast (MDA-MB-231 and MCF-7) tumors. The results provided evidence that TQ,
at non-toxic levels, showed significant inhibition of viability in these cancer cells by
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inhibiting Akt phosphorylation and promoting activation of the mitochondrial signaling
pro-apoptotic pathway (Attoub, et al, 2013). They further demonstrated the anticancer
potential of TQ in combination with chemotherapeutic drugs such as cisplatin. TQ was
shown to synergize with the DNA-damaging agent cisplatin in order to inhibit cell
viability (Attoub, et al, 2013).
TQ has shown to induce apoptosis in tumor cells which is a key mechanism for 
the effectiveness of anti-cancer drugs. Studies show that TQ induces apoptosis using both 
p53-dependent and p53-independent mechanisms (Effenberger and Schobert, 2011; Gali-
Muhtasib, et al, 2006; El-Mahdy, M, et al., 2005) as detected by chromatin condensation, 
translocation of phospatidyl serine across the plasma membrane, DNA fragmentation 
(Abukhader, 2013) and activation of the intrinsic apoptotic pathway (Attoub, et al., 
2013). It has been found to delay tumour growth in vivo through cell cycle arrest in 
several xenograft models (El-Mahdy, et al, 2005). Moreover, several studies reported a 
role for TQ in “suppressing COX-2, survivin, Bcl family proteins, STAT3 
phosphorylation of NF-kB, Akt activation, extracellular signal regulated kinase
phosphorylation (ERK) and inhibition of telomerase activity” (Gurung, et al, 2010; Arafa,
et al, 2011; Sethi, et al, 2008; Banerjee, et al, 2009; Li, 2010; Yi, et al, 2008).
A recent study by Ahmad et al, (2013) demonstrated that TQ suppresses
metastasis of melanoma cells by inhibiting the NLRP3 (NACHT, LRR, and pyrin domain
containing protein 3) inflammasome (Ahmad, et al, 2013). The inflammasome is a
multiprotein complex which regulates caspase – 1 activation and IL-1β and IL-18
secretion when activated (Ahmad, et al, 2013). The study showed that TQ inhibits the
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migration of both mouse and human melanoma cells in vitro and metastasis of mouse
cells in vivo, thus suggesting a potential role for TQ as an immunotherapeutic agent in the
control and prevention of metastatic melanoma (Ahmad, et al, 2013). Salomi et al (1990)
showed that N. sativa extracts when applied topically in mice, inhibited two-stage
initiation/promotion of skin carcinogenesis (Khan, et al, 2011). Then suggested that N.
sativa and one of its major metabolites, TQ, may provide a good starting point for the
development of an anti-melanoma therapeutic.
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1.13. Thesis objectives
The first objective of this study was to test the effect of two different extracts of N. 
sativa (ethanolic, aqueous) on two malignant (murine melanoma B16-BL6, brain cancer
T98G) and three non-malignant (human embryonic kidney 293T, human breast HBL 100, 
human salivary gland HSG) cell lines.
The second objective of this study was to determine the mechanism of action of N. 
sativa on the murine melanoma B16-BL6 cell death pathway and focus on apoptotic 
pathways.
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Chapter 2. Materials and Methods
2.1. Drug preparation 
The N. sativa seeds used in this study were obtained from Paris Natural Foods 
store of Sudbury, Canada (made by Sunn Herbal, Vancouver, BC, Canada: 150812). For 
the preparation of the alcoholic extract, 100mg of N. sativa was mixed with 1 ml of 70% 
ethanol.  For the preparation of the aqueous extract, 100mg of N. sativa was mixed with 1 
ml of water. Both suspensions were boiled for one hour and then filtered through 0.22 
μM and stored at -80 °C until used.
2.2 Tissue culture
The cell lines that were tested with N. sativa included the B16-BL6 (murine 
melanoma), T98G (brain cancer), HBL 100 (human breast), 293T (human embryonic 
kidney) and HSG (human salivary gland). Cell lines were obtained from the American 
Type Culture Collection, (Manassas, VA). All of these cells were maintained in 
Dulbecco’s Modified Essential Medium (DMEM, Hyclone, Logan, UT) which was 
supplemented with 10% fetal bovine serum (Hyclone), 100 µg/ml streptomycin, and 100 
µ/ml penicillin (Invitroogen, Burlington, ON) at 37°C in a humidified atmosphere in a 
5% CO2 incubator.
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2.3. MTT assay (Methyl Tetrazolium Blue)
To assess the effect of the N. sativa extracts on the growth of different malignant 
and non-malignant cell lines, the MTT assay was performed. The reduction of MTT to an 
insoluble formazan purple salt can be quantified by measuring the absorbance of light at 
540nm. Since reduction can only occur in living cells, the color intensity is an important 
measure of the viability of cells. Approximately, 2x103 cells/well were added a 96-well 
plate and incubated at 37°C with 5% CO2 for 24 hours. The cells were treated with 
various concentrations (0.05, 0.1, 0.5, 1, and 2 %) of the N. sativa extracts. The viability 
of the cells determined each day for five days. 10 µl of MTT was added to each well at a 
final concentration of 0.4 µg/ml and incubated for 4 hours. The media was removed and 
100 µl of dimethyl sulfoxide (DMSO) was pipetted into each well to solubilize the 
formazan crystals. The absorbance was then measured at 540 nm using a (SpectraMax 
340 PC 389) plate reader. The data for cell growth at each concentration was statistically 
analyzed by performing ANOVA using Graph Pad Prism Software.
2.4. Morphological analysis
Morphological changes in cells treated with various doses (0.05, 0.1, 0.5, 1, and 2
%) of both ethanolic and aqueous extracts of N. sativa were documented using an 
inverted phase contrast Axiovert 100 microscope Northern Eclipse software.
26
2.5. Cell Staining assay (Acridine Orange/Ethidium Bromide) 
Acridine orange and ethidium bromide staining was performed to visualize 
changes in cellular morphology associated with apoptosis. B16-BL6 cells were plated on 
glass cover slips and incubated overnight at 37°C with 5% CO2. The cells were then 
treated with the indicated N. sativa preparations for different time points (24, 48, and 72). 
Camptothecin was used as a positive control for apoptosis. The cells were stained with 10
g/ml of acridine orange (Sigma-Aldrich) and 10 g/ml of ethidium bromide (Sigma-
Aldrich) at 37°C for 15 minutes. The coverslips were rinsed in PBS, and mounted onto a
glass slide. The fluorescence was viewed using an LSM 510 fluorescence microscope.
2.6. TUNEL assay (terminal deoxynucleotidyl transferase dUTP nick end 
labeling) 
The tunel assay was performed to detect for DNA fragmentation that results from 
apoptosis (Roche, Laval, QB). B16-BL6 cells were plated onto glass cover slips, 
incubated for 24 hours at 37°C with 5% CO2 and then treated with media containing the 
indicated N. sativa preparations for three different time points (0, 48 and 72 hours). 
Camptothecin was used as a positive control for apoptosis.  The cells were washed with 
PBS and then fixed in 1 ml of 10% formaldehyde. 1 ml of 10% formaldehyde was added 
to each well and incubated at 4°C for 5 minutes. The fixative solution was removed, the 
cells washed twice with PBS and then permeabilized using 1% triton X- 100 in PBS 
permeabilisation solution incubated for 3 minutes at 4°C and then washed twice with 
PBS. 50 µl of the Tunel reaction mixture was added to each well and incubated for 1 
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hour.  Cells were viewed using a Zeiss LSM5 fluorescence microscope and images were 
recorded.
2.7. Caspase activity assay (caspase colorimetric protease assay sampler kit)
The caspase activity assay was performed to determine the increased enzymatic 
activity of caspases-2, -3, -6, -8, -9 in apoptotic cells by a colorimetric reaction
(Apotarget Caspase Colometric Protease Assay Sampler Kit, Invitrogen Corporation).
B16-BL6 cells cultured on 150x20 cm plate were treated with the indicated N. sativa
preparations for 24 hours. Cells corresponding to 3-5 x 106 cells/sample were lysed in 50 
µl of chilled Cell Lysis Buffer at 4 °C, incubated on ice for 10 minutes, and then 
centrifuged at 10,000 x g for 1 minute. The supernatants were transferred to a new tube 
and incubated on ice. The supernate were diluted to a concentration of 50-200 µg protein 
per 50 µL Cell Lysis Buffer (1- 4 mg/mL). To each sample, 50 μL of 2x Reaction Buffer 
(containing 10 mM DTT) was added. Then, 5 μL of the 4 mM colorimetric substrate (200 
μM final concentration) was added to each sample and incubated at 37 °C for 1 - 2 hours. 
The (96-well) plate was read on a (SpectraMax 340 PC 389) plate reader using 405 nm 
wavelength. The fold-increase in caspases-2, -3, -6, -8, -9 activity were determined by 
comparison with uninduced control. Camptothecin was used as a positive control 
treatment for caspase activation.  
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2.8. HPLC (High-performance liquid chromatography)
20 gm of N. sativa powder extract was suspended and boiled for one hour in 200 
ml of 70% ethanol. The mixture was filtered through 1 mm whatman filter paper and the 
filtrate was frozen at -80 ºC and dried using a lyophilizer. For some experiments the N. 
sativa extract was fractionated over an ethanol-water gradient. For these experiments, the 
N. sativa extract was mixed in 20 gm poly (vinylpolypyrrolidone) matrix (Sigma 
Chemical, St Louis, MO) and 200 ml water. The mixture was poured into a column and 
eluted with different concentration of ethanol to fractionate it into different fractions. It 
was eluted with 200 ml each of water, 20% ethanol, 40% ethanol, 60% ethanol, 80% 
ethanol, and 100% ethanol. The fractions were freeze dried and the resulting powder
weighed. Resuspended extracts were characterized using HPLC on a Breeze 2 
chromatography system (Waters Inc, Toronto, ON). Each fraction of N. sativa was 
separated using a Sunfire C18 column 3.5 μm resin 4.6x100 mm. The solvents (A) 60 
volumes 10 mM phosphate buffer, pH 6.6, 20 volumes acetonitrile, and 20 volumes 
methanol, and (B) 30 volumes 10 mM phosphate buffer, pH 6.6, 35 volumes acetonitrile, 
and 25 volumes methanol, were used. To determine the alkaloid composition of these 
fraction, solvents were pumped through the column at 1 ml/min. Over a time period of 40 
min, the solvents were mixed using a liner gradient starting with 100% buffer A and 
finishing with 100% B. Then, for 10 min, 100% buffer B was pumped through column. 
Lastly, for 5 min, a gradient starting with 100% B and finishing with 100% was pumped 
through the column. The N. sativa components were identified at a wavelength of 245 
nm. The identified peaks were compared to the (Thymoquinone) standard (Sigma).   
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2.9. Statistical analysis
In this study, the data were presented as mean ± standard deviation of three 
independent experiments performed in triplicate and were analysed by ANOVA using 
Graph Pad Prism Software. In the caspase activity assay, the data were presented from 
two experiments.
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Chapter 3. Results
3.1. Cell viability
The anti-proliferative effect of N. sativa against malignant (B16-BL6, TG8G) cell 
lines and non-malignant (293T, HSG, HBL100) cell lines was determined using the MTT 
assay. Treatment with the ethanolic extract of N. sativa at a high concentration (2%)
showed a significant (p<0.05) inhibition of 90% cell growth in the malignant cell lines
B16-BL6 and T98G compared to other concentrations (0.05%, 0.5%) and untreated cells
(Figures 3.1,.3.3). Treatment with the aqueous extract of N. sativa at a high concentration 
(2%) showed a significant (p<0.05) decrease in the number of B16-BL6 and T98G cells 
by ~50% (Figures 3.2, 3.4) compared to other concentrations (0.05%, 0.5%) and
untreated cells.
Treatment with the ethanolic extract of N. sativa at a high concentration (2%) on 
non-malignant cell lines (HEK 293T, HSG, HBL 100) completely inhibited cell growth 
compared to other concentrations (0.05%, 0.5%) and untreated cells (Figures 3.5, 3.7, 
3.9). Treatment with the aqueous extract of N. sativa at all concentrations (0.05, 0.5, and 
2 %) on non-malignant cell lines (HEK 293T, HSG, HBL 100) caused an increase of cell 
growth over time (Figures 3.6, 3.8, 3.10).
In all experiments, the ethanolic extract of N. sativa was more effective in 
inhibiting cell growth than was the aqueous extract of N. sativa.
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Figure 3.1. Effect of the N. sativa ethanolic extract on B16-BL6 cell
proliferation.
The effect on cell proliferation in response to treatment with N. sativa was assessed using
the MTT (Thiazolyl Blue Tetrazolium Bromide) assay. B16-BL6 cells were exposed to 
increasing concentrations of 0.05% panel A, 0.5% panel B%, and 2% panel C of N. sativa
ethanolic extract and cultured for five days. Optical density at 540 nm was determined 
each day and the average ± standard deviation for 8 values was determined. Graphs show 
the average optical density for each day of treatment for one of at least 3 independent 
experiments.
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Figure 3.2. Effect of the N. sativa aqueous extract on B16-BL6 cell
proliferation.
The effect on cell proliferation in response to treatment with N. sativa was assessed using 
the MTT assay. B16-BL6 cells were exposed to increasing concentrations 0.05% (panel 
A), 0.5% (panel B), and 2% (panel C) of N. sativa aqueous extract and cultured for five 
days. 
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Figure 3.3. Effect of the N. sativa ethanolic extract on T98G cell 
proliferation.
The effect on cell proliferation in response to treatment with N. sativa was assessed using
the MTT assay. T98G cells were exposed to increasing concentrations 0.05% (panel A), 
0.5% (panel B), and 2% (panel C) of N. sativa ethanolic extract and cultured for five 
days. 
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Figure 3.4. Effect of the N. sativa aqueous extract on T98G cell 
proliferation.
The effect on cell proliferation in response to treatment with N. sativa was assessed using 
the MTT assay. T98G cells were exposed to increasing concentrations 0.05% (panel A), 
0.5% (panel B), and 2% (panel C) of N. sativa aqueous extract and cultured for five days
38
0.05
DAYS
ab
so
rb
an
ce
 5
40
 n
m
0 2 4 6
0.0
0.5
1.0
1.5
2.0
2.5
0.05% H2 O
0.05% B. seed
Control
0.5
DAYS
ab
so
rb
an
ce
 5
40
 n
m
0 2 4 6
0.0
0.5
1.0
1.5
2.0
2.5
0.5% H2O
0.5% B. seed
Control
2
DAYS
ab
so
rb
an
ce
 5
40
 n
m
0 2 4 6
0.0
0.5
1.0
1.5
2.0
2.5
2% H2 O
2% B. seed
Control
39
Figure 3.5. Effect of the N. sativa ethanolic extract on the proliferation of
non-malignant HEK 293T cells. 
The effect on cell proliferation in response to treatment with N. sativa was assessed using
the MTT assay. HEK 293T cells were exposed to increasing concentrations 0.05% (panel 
A), 0.5% (panel B), and 2% (panel C) of N. sativa ethanolic extract and cultured for five 
days. 
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Figure 3.6. Effect of N. sativa aqueous extract on the proliferation of non-
malignant HEK 293T cells. 
The effect on cell proliferation in response to treatment with N. sativa was assessed using
the MTT assay. HEK 293T cells were exposed to increasing concentrations 0.05% (panel 
A), 0.5% (panel B), and 2% (panel C) of N. sativa aqueous extract and cultured for five 
days.
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Figure 3.7. Effect of the N. sativa ethanolic extract on the proliferation of 
non-malignant HSG cells.
The effect on cell proliferation in response to treatment with N. sativa was assessed using 
the MTT assay. HSG cells were exposed to increasing concentrations 0.05% (panel A), 
0.5% (panel B), and 2% (panel C) of N. sativa ethanolic extract and cultured for five 
days. 
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Figure 3.8. Effect of the N. sativa aqueous extract on the proliferation of 
non-malignant HSG cells.
The effect on cell proliferation in response to treatment with N. sativa was assessed using
the MTT assay. HSG cells were exposed to increasing concentrations 0.05% (panel A), 
0.5% (panel B), and 2% (panel C) of N. sativa aqueous extract and cultured for five days.
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Figure 3.9. Effect of the N. sativa ethanolic extract on the proliferation of 
non-malignant HBL100 cells.
The effect on cell proliferation in response to treatment with N. sativa was assessed using
the MTT assay. HBL100 cells were exposed to increasing concentrations 0.05% (panel 
A), 0.5% (panel B), and 2% (panel C) of N. sativa ethanolic extract and cultured for five 
days.
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Figure 3.10. Effect of N. sativa aqueous extract on the proliferation of
non-malignant HBL100 cells.
The effect on cell proliferation in response to treatment with N. sativa was assessed using
the MTT assay. HBL100 cells were exposed to increasing concentrations 0.05% (panel 
A), 0.5% (panel B), and 2% (panel C) of N. sativa aqueous extract and cultured for five 
days. 
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Figure 3.11. Comparison of the effect N. sativa extracts on malignant and 
non-malignant cell lines.
The effect on cell proliferation in response to treatment with the high dose (2%) of N. 
sativa extract (both ethanol and aqueous) for B16-BL6, T98G, HEK, HSG, and HBL100
was assessed using the MTT assay, and all of the cell lines were cultured for five days.
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3.2. Stability of the N. sativa ethanolic extract
The ethanolic extract of N. sativa was stored at 4 °C for four weeks to test the 
stability of the active compounds in the N. sativa. The effect of the ethanolic extract of N. 
sativa on the growth of B16-BL6 cells was tested each week. The growth assays showed 
very similar results for each week indicating that the N. sativa ethanolic extract was
stable and maintained the ability to inhibit cell growth (Figure 3.12)
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Figure 3.12. The stability of the N. sativa ethanolic extract (4 weeks).
For four weeks, the effect on cell proliferation in response to treatment with N. sativa
ethanolic extract was assessed using the MTT assay. B16-BL6 cells were exposed to the 
high dose (2%) of N. sativa ethanolic extract and cultured for several days.
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3.3. Morphological changes in malignant (B16-BL6) cell line after treatment 
with N. sativa.
The morphology of B16-BL6 cells treated with N. sativa was examined to 
determine any effects of treatment on cell morphology. B16-BL6 cells were treated with 
low (0.05%) and high (2%) concentrations of N. sativa for 72 h at 37°C. B16-BL6 cells
that were treated with a high dose (2%) of the N. sativa ethanolic extract showed visible 
damage to the cells and a decrease in cell number (Figure 3.13 A). There was no 
morphological difference in the B16-BL6 cells that were treated with a low dose (0.05%) 
of the N. sativa ethanolic extract compared to the control cells (Figure 3.13 A). The cells 
appeared to be similar in number and in shape. 
B16-BL6 cells were also treated with a high dose (2%) of the N. sativa aqueous
extract which was able to reduce number of cells significantly compared to the control
cells although not as much as cells treated with the high dose ethanol extract (Figure 3.13
B). There was no morphological difference in B16-BL6 cells that were treated with a low 
dose (0.05 %) of the N. sativa aqueous extract compared to the control cells (Figure 3.13 
B). 
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Figure 3.13. Morphological changes in B16-BL6 cells exposed to N. sativa
for 72 h.
B16-BL6 cells were treated with the ethanolic and aqueous extracts of N. sativa at
various concentrations (0.05% and 2%) and incubated for 72 h at 37°C. Before the 
pictures were taken, 10 µl of MTT was added to the treated cells at a final concentration 
of 0.4 g/ml and incubated for 4 hours. Experiments were performed in triplicate. Figure 
A is the ethanolic extract of N. sativa. Figure B is the aqueous extract of N. sativa.
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3.4 Morphological changes in non-malignant (239T) cell line after treatment 
with N. sativa.
The morphology of 239T cells treated with N. sativa was examined to determine 
any effects of treatment on cell morphology. 239T cells were treated with a low (0.05%) 
and a high (2%) concentrations of N. sativa for 72 h at 37°C. 239T cells that were treated 
with a high dose (2%) of the N. sativa ethanolic extract showed visible damage to the 
cells and decrease in cell number (Figure 3.14 A). There was no morphological 
difference in 239T cells treated with a low dose (0.05 %) of the N. sativa ethanol extract 
compared to the control cells (Figure 3.14 A). 
239T cells treated with a high dose (2%) of the N. sativa aqueous extract showed an 
increase in the cell number and no change in the morphology of the 239T cells (Figure 
3.14 B). There was no morphological difference in 239T cells that were treated with a
low dose (0.05%) of the N. sativa aqueous extract compared to the control cells (Figure 
3.14 B). 
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Figure 3.14. Morphological changes in 239T cells exposed to various 
concentrations of N. sativa for 72 h.
239T cells were treated with ethanolic and aqueous extracts of N. sativa at various 
concentrations (0.05% and 2%) and incubated for 72 h at 37°C. Before the pictures were 
taken, 10 µl of MTT was added to the treated cells at a final concentration of 0.4 g/ml 
and incubated for 4 hours. Experiments were performed in triplicate. Figure A is the 
ethanolic extract of N. sativa. Figure B is the aqueous extract of N. sativa.
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3.5. Induction of Apoptosis
B16-BL6 cells were stained with acridine orange and ethidium bromide to 
observe the nuclear changes and the formation of apoptotic bodies that are characteristic 
of apoptosis. B16-BL6 cells were exposed to different (0.05% and 2%) concentrations of 
N. sativa for 72 h at 37°C. B16-BL6 cells that were treated with a high dose (2%) of N. 
sativa ethanolic extract showed a significant change in cell morphology; membrane 
blebbing and complete destruction of nuclear structure (Figure 3.15). There were small
morphological changes in B16-BL6 cells treated with a low dose (0.05%) of N. sativa
ethanolic extract compared to the control cells (Figure 3.16). B16-BL6 cells that were 
treated with a high dose (2%) of N. sativa aqueous extract contain bright green dots in the 
nuclei as a result of nuclear fragmentation and chromatin condensation (Figure 3.15). 
There were no morphological changes in B16-BL6 cells treated with a low dose (0.05 %) 
of N. sativa aqueous extract compared to the untreated control cells (Figure 3.16). 
B16-BL6 cells were stained with the TUNEL reaction mixture to detect DNA 
fragmentation which occurs during the late stage of apoptosis. B16-BL6 cells were 
exposed to different (0.05% and 2%) concentrations of N. sativa for 72 h at 37°C. B16-
BL6 cells that were treated with a high dose (2%) of N. sativa ethanolic extract showed a 
significant increase in TUNEL staining, which indicated apoptosis, compared to a low 
dose (0.05%)  and the untreated control cells (Figure 3.17, 3.18). B16-BL6 cells treated 
with a high dose (2%) of N. sativa aqueous extract showed a small increase in TUNEL 
staining compared to the control cells (Figure 3.17). 
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Figure 3.15. Treatment with N. sativa for 72 h induced apoptosis in B16-
BL6 cells using acridine orange/ ethidium bromide staining: Inlayed view 
of treated cells.
B16-BL6 cells were treated with the ethanolic and aqueous extracts of N. sativa at 
various concentrations (0.05% and 2%). Camptothecin was used as a positive control for 
apoptosis. After 72 h of incubation at 37°C, apoptotic cells were detected by acridine 
orange (green) and of ethidium bromide (red) staining. Pictures were viewed under a 
LSM 510 fluorescence microscope, and experiments were done in triplicate.
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Figure 3.16. Treatment with various concentrations of N. sativa for (24, 
48, and 72 h) induced apoptosis in B16-BL6 cells using acridine orange/ 
ethidium bromide staining: inlayed view of treated cells.
B16-BL6 cells were treated with the ethanolic and aqueous extracts of N. sativa at 
various concentrations (0.05% and 2%). Camptothecin was used as a positive control for 
apoptosis. After different time points (24, 48, and 72 h) of incubation at 37°C, apoptotic 
cells were detected by acridine orange (green) and of ethidium bromide (red) staining. 
Pictures were viewed under a LSM 510 fluorescence microscope, and experiments were 
done in triplicate.
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Figure 3.17. Treatment with N. sativa for 72 h induced apoptosis in B16-
BL6 cells using the TUNEL assay: Inlayed view of treated cells.
B16-BL6 cells were treated with the ethanolic and aqueous extracts of N. sativa at 
various concentrations (0.05% and 2%) of N. sativa. Camptothecin was used as a positive 
control for apoptosis. After 72 h of incubation at 37°C, apoptotic cells were detected by 
TUNEL assay. Pictures were viewed under a LSM 510 fluorescence microscope, and 
experiments were done in triplicate.
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Figure 3.18. Treatment with various concentrations of N. sativa for (24, 
48, and 72h) induced apoptosis in B16-BL6 cells using the TUNEL assay.
B16-BL6 cells were treated with the ethanolic and aqueous extracts of N. sativa at
various concentrations (0.05% and 2%) of N. sativa. Camptothecin was used as a positive 
control for apoptosis. After (24, 48, and 72 h) of incubation at 37°C, apoptotic cells were 
detected by TUNEL assay. Pictures were viewed under a LSM 510 fluorescence 
microscope, and experiments were done in triplicate.
70
71
3.6. Effect of N. sativa on the expression of caspase -2, -3, -6, -8 and -9 in B16-
BL6 cells
Caspase activity assay was used to determine whether treatment with N. sativa
caused apoptosis. This assay uses spectroscopy to detect of the chromophore p-
nitroaniline (p-NA) after cleavage from the labeled peptide substrate VDVAD (for 
caspase-2), DEVD (for caspase-3), VEID (for caspase-6), IETD (for caspase-8), or
LEHD (for caspase-9). B16-BL6 cells were treated with ethanolic and aqueous extracts
of N. sativa at a high concentration (2%) for 24 h at 37°C. For each essay, 3x106 cells 
were lysed in 50 µl of lysine buffer and incubated in ice 10 minutes. The B16-BL6 cell 
lysate were incubated with the individual substrates at 37°C for 2 h, and the caspase 
activities were determined by measuring the changes in absorbance at 405 nm using a 
plate reader. B16-BL6 cells that were treated with the high concentration of the ethanolic 
extract of N. sativa showed a significant increase in caspase -2, -3, -6, -8, and -9. Caspase 
-3 activity was the highest compared to the control cells (Figure 3.19). B16-BL6 cells 
were treated with the high concentration of the aqueous extract of N. sativa showed a 
smaller increase in caspase -2, -3, -6, -8, and -9. Caspase -8 activity was the highest
compared to the control cells (Figure 3.19). Experiments were performed in duplicate 
assays. 
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Figure 3.19. Effect of N. sativa on the expression of caspase -2, -3, -6, -8 
and -9 in B16-BL6 cells.
Caspase activities were determined by colorimetric assays using caspase-2, -3, -6, -8 and 
-9 activation kits (Life technology). B16-BL6 were treated with high dose (2%) ethanolic 
or aqueous extracts of N. sativa for 24 h. Camptothecin was used as a positive control for 
apoptosis.The caspase activities were determined by measuring changes in absorbance at 
405 nm using a (SpectraMax 340 PC 389) plate reader.
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3.7. HPLC
High performance liquid chromatography was performed to separate the 
components of N. sativa extracts and to indicate the presence of any unknown 
compound(s) that could be responsible for inhibiting cancer cell proliferation. Ethanol
extract has more peaks than water extract. N. sativa extracts were fractionated into 
various ethanol fraction starting with the aqueous fraction, 20% ethanol, 40% ethanol, 
60% ethanol, 80% ethanol, and 100% ethanol subjected to HPLC as described in section 
3.8. By comparing the spectra and retention times of standards, these fractions were 
characterized for the presence of any peaks. Number of peaks change for different 
fractions (100% ethanol fraction has very low levels of alkaloids).
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Figure 3.20. HPLC analysis of N. sativa extracts (water, ethanol)
N. sativa extracts were analyzed by using a high performance liquid chromatography 
method. Each extract (water, ethanol) of N. sativa was subjected to HPLC and peaks 
identified using a wavelength of 245 nm. Thymoquinone was used as a known compound 
standard to identify the peaks of the chromatogram in N. sativa extracts. Chromatogram 
A is ethanol extract, and chromatogram B is water extract.
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Figure 3.21. HPLC analysis of N. sativa extract (20% ethanol, 40% ethanol, 
60% ethanol, 80% ethanol, 100% ethanol)
N. sativa extracts were analyzed using high performance liquid chromatography. The N. 
sativa extract was fractionated using an ethanol series and, each fraction (20% ethanol,
40% ethanol, 60% ethanol, 80% ethanol, 100% ethanol) of N. sativa was subjected to 
HPLC and peaks using a wavelength of 245 nm. Thymoquinone was used as a known 
compound standard to identify the peaks of the chromatogram of N. sativa extracts. 
Chromatogram A is ethanol extract, B is water fraction, C is 20% ethanol fraction, D is
40% ethanol fraction, E is 60% ethanol fraction, F is 80% ethanol fraction, and G is 
100% ethanol fraction.
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3.8. Individual components of N. sativa
The anti-proliferative effect of Thymoquinone (Sigma) against the aggressive 
murine melanoma cell line B16-BL6 was determined using the MTT assay. The result 
showed significant (p<0.05) cell inhibition in response to treatment with the high (100 
nM) concentration of Thymoquinone compared to the low (10 nM) concentration (Figure 
3.22).
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Figure 3.22. Effect of the Thymoquinone ethanolic extract on B16-BL6 cell 
proliferation.
The effect on cell proliferation in response to treatment with Thymoquinone was assessed 
using the MTT assay. B16-BL6 cells were exposed to a low dose (10 nM) and a high
dose (100 nM) of Thymoquinone and cultured for four days. 
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Chapter 4. Discussion
Melanoma is one of the diseases which is considered to be resistant to cytotoxic 
agents causing a high rate of deaths (Looi, et al, 2013). For that reason, finding different 
sources of anticancer agents has become crucial to identify cytotoxic agents that have
activity agents on melanoma (Looi, et al, 2013). Natural products are gaining more 
interest not just because of their anticancer effects, but also of their abundance (Gali-
Muhtasib, et al, 2006).
Recently, one important studied plant was N. sativa (Gali-Muhtasib, et al, 2006). 
It has been used in some parts of Asia as a source of spice and food preservatives, as well 
as for its ability to prevent many diseases for thousands of years (Santoso, et al, 119). 
Many reports from different laboratories have shown indications of N. sativa health 
benefits, such as in vitro antioxidant and anticancer activities (Dilshad, et al, 2012;
Randhawa & Alghamdi, 2011; Ahmad, et al, 2013). It has been shown that a methanol 
extract of N. sativa was able to induce in vitro cytotoxicity in the human prostate cancer 
(PC3) cell line, and it has been also shown that the ethanolic extract and chloroform 
fraction of seed extracts of N. sativa induced apoptosis in HeLa cells (Hasan, et al, 2013; 
Ayman, 2012).
This study was designed to investigate the effect of N. sativa on malignant and 
non-malignant cell lines. It was shown that the 70% extracted ethanol of N. sativa had a 
cytotoxic effect and was able to inhibit the growth of malignant and non-malignant cell
lines. In contrast, N. sativa extracted with water had a reduced ability to reduce the cell 
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growth of malignant cell lines and could cause an increase in cell growth for some of 
non-malignant cell lines. The ethanolic extract of N. sativa had the greatest anti-
proliferative activity, and that may be because the active compounds of N. sativa were 
more soluble in 70% ethanol than the aqueous extract. These data support the idea of 
other studies that there is an effective anti-cancer components in N. sativa.
4.1. Anti-proliferative activity of N. sativa
It has been reported in some studies that N. sativa extract has cytotoxic effects 
which can have a huge influence on several types of cancer cell lines (Al-Sheddi, et al, 
2014; Hasan, et al, 2013; Ayman, 2012). Al-Sheddi’s study found that there was a strong 
cytotoxic effect by using both N. sativa seed and its oil extract to treat a human lung 
cancer cell line (A-549), and they both significantly reduced cell growth of A-549 cells
(p<0.001) (Al-Sheddi, et al., 2014).
The current study used the thiazolyl blue tetrazolium bromide (MTT) assay to 
determine the cell viability of various malignant and non-malignant cell lines after 
treatment with N. sativa. Since the MTT assay measures an activity of living cells, its
uptake and change to soluble MTT into purple formazan products is a measure of cells 
number. (Arafa, et al, 2011). Our MTT assays were carried out over several days which 
allowed a measure of changing cell numbers, on cell growth. 
The results showed that treatment with the highest dose (2%) of the N. sativa
ethanolic extract inhibited the cell growth in both the malignant (B16-BL6, T98G) and 
non-malignant (293T, HSG, and HBL 100) cell lines. However, treatment with the 
highest dose (2%) of the N. sativa aqueous extract showed lower levels of inhibition in 
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cell growth in all tested malignant cell lines. On the other hand, all non-malignant cell 
lines were able to continue proliferating when treated with the aqueous extract of N. 
sativa at all concentrations (0.05, 0.1, 0.5, 1 and 2 %). This suggests that the ethanolic 
and aqueous extracts contained some different compounds and that the ethanolic extract 
contained a potent cytotoxic agents.
In Al-Sheddi’s study, after 24h of treatment with N. sativa seed extract at 0.25 
mg/ml and higher doses, the typical cell morphology and cell adhesion capacity of the 
human lung cancer (A-549) cells were changed (Al-Sheddi, et al, 2014). Moreover, 
treatment with N. sativa seed oil at 0.1 mg/ml had the ability to start reducing the shape 
and cell adhesion capacity of the human lung cancer (A-549) cells (Al-Sheddi, et al, 
2014).
In our study, the morphology of cells treated with N. sativa was examined to 
determine any effects of treatment on cell morphology. After 72 h of treatment of B16-
BL6 cells with the highest dose (2%) of N. sativa ethanolic extract there was obvious 
damage to the cells as shown by changes in cell shape and a decrease in cell number. 
Whereas treatment of malignant cell with the highest dose (2%) of N. sativa aqueous 
extract was able to reduce the number of cells and started to change the typical shape of 
the cells. From these results, it was clearly indicated that N. sativa ethanolic extract has 
more cytotoxic effects on cell growth than N. sativa aqueous extract. Therefore, N. sativa
ethanolic extract has potent anticancer chemicals which induce apoptosis that were not 
found in the aqueous extract.
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Our in vitro results for the murine melanoma cell line B16-BL6, showed that 
treatment with low doses of N. sativa resulted in inhibition of cell growth ranging from 
5% to 30% fewer cells. B16-BL6 cells treated with the high dose of N. sativa for 24 h
showed a huge inhibition of cell growth greater than 50%. From these results, we suggest
that N. sativa seeds have effective anticancer components causing the death of cancer 
cells. 
4.2. N. sativa and the Induction of Apoptosis
Anticancer drugs derived from natural products can have different mechanisms of 
action, althugh the mechanism is based on their ability to induce apoptosis (Shafi, et al.,
2009). Apoptosis is an active physiological mechanism that cause obvious morphological 
changes to the cells, such as DNA fragmentation, chromatin condensation, membrane 
blebbing, cell shrinking, and apoptotic body formation (Shafi, et al, 2009). Several 
studies have found that natural products are able to regulate apoptotic pathways (Daniel, 
et al, 2006), and from our results it is proposed that N. sativa is able to induce apoptosis 
in B16-BL6 cells. 
In the present study, we investigated if murine melanoma B16-BL6 cells treated 
with N. sativa extracts used apoptosis as its mode of action to decrease cell growth. 
Apoptosis was investigated by examining the morphological features of cells such as 
nuclear chromatin condensation and DNA fragmentation. TUNEL assays and acridine 
orange/ethidium bromide staining assays were used to determine whether the cytotoxicity 
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activity of N. sativa is due to the induction of apoptosis. B16-BL6 cells treated with the 
highest dose of the ethanolic or aqueous extracts of N. sativa were stained with acridine 
orange/ethidium bromide. Acridine orange is a fluorescent dye which stains DNA in both 
dead and live cells green, and ethidium bromide is a sensitive dye which stains DNA in
cells that have lost membrane integrity red.
We have shown that B16-BL6 cells treated with the N. sativa ethanolic extract 
induced DNA fragmentation after 72 h, whereas B16-BL6 cells treated with the N. sativa
aqueous extract for 72 h was not as effective as the N. sativa ethanolic extract.
Moreover, to identify DNA fragmentation which happens during the late stage of 
apoptosis, a TUNEL assay was performed. The results showed that B16-BL6 cells treated 
with both extracts of N. sativa at 0 h did not cause DNA fragmentation. On the other 
hand, B16-BL6 cells were highly apoptotic after 72 h of treatment due to DNA 
fragmentation. Cells treated with the high dose of the N. sativa ethanolic extract showed 
higher levels of DNA fragmentation than cells treated with the aqueous extract. From 
these last two experiments, it is indicated that the N. sativa ethanolic extract has a 
stronger activity more to induce apoptosis and cause DNA fragmentation than the N. 
sativa aqueous extract.
Recent studies using the TUNEL assay demonstrated that the methanolic extract 
of N. sativa seeds, in dose-dependent manner, induced DNA fragmentation caused by 
apoptosis in human cervical cancer cells and MDA-MB-231 cancer cell line (Hasan, et al, 
2013; Dilshad, et al, 2012).
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In addition, apoptosis depends on a group of intracellular proteases that have 
cysteine in their active sites, called caspases (Alberts, et al, 2008). Caspases play an
important role in the apoptosis mechanism because many of the morphological and 
biochemical changes are associated with caspases-dependent degradation (Alberts, et al, 
2008). Caspases exist in the cells as inactive pro-caspases which are activated by 
proteolytic cleavage to generate the active proteases (Alberts, et al, 2008).
To confirm that B16-BL6 cells were undergoing apoptosis in response to 
treatment with N. sativa, a caspase activity assay was performed. In both extracts of N. 
sativa, B16-BL6 cells showed increased activity for caspase -2, -3, -6, -8, and -9. 
Treatment with the high dose of N. sativa ethanolic extract for 24 h showed a huge 
increase in all caspase activity, and caspase -3 activity was the highest compared to the 
control cells. In contrast, treatment with the high dose of N. sativa aqueous extract for 24
h showed a smaller increase in all caspase activity, and caspase -8 activity was the 
highest compared to the control cells. N. sativa extracts activated both the extrinsic and 
intrinsic pathways. This could be caused by the presence of several compounds in the 
mixture which could activate both pathways.
We have presented evidence showing that the ethanolic extract of N. sativa was 
able to be more effective in inducing apoptosis than the aqueous extract. Hasan’ study 
suggested that N. sativa activates intrinsic and extrinsic death pathway by increased
activity of caspase-3, 8, and 9 in human cervical cancer cells (Hasan, et al, 2013). N. 
sativa extracts contain TQ which is known to cause cell death, probably through 
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apoptosis. Interestingly, TQ is more soluble in ethanol and would be expected to be a 
higher concentration in the ethanolic extract compared to the aqueous extract.
4.3. Characterization of N. sativa
A high performance liquid chromatography method was used to identify the 
phytochemical components in N. sativa. In recent studies, many known bioactive
components were isolated from N. sativa by HPLC include, thymol, thymohydroquinone, 
thymoquinone, and dithymoquinone (Muzaffar, 2013). However, many studies reported 
that thymoquinone is the major active constituent of N. sativa (Muzaffar, 2013; Gali-
Muhtasib, et al, 2006). Experimental studies have also revealed the chemotherapeutic 
potential of thymoquinone for anti-cancer activity in combination with clinically used 
drugs like doxorubicin, cisplatin and isofosfamide in certain cancer cell lines including
the 518A2 melanoma (Effenberger and Schobert, 2011). It was observed that when 
518A2 melanoma cells were treated with equimolar mixtures of doxorubicin and TQ, TQ 
caused an increase in reactive oxygen species (ROS) leading to growth inhibition
(Effenberger and Schobert, 2011).
The purpose of fractionating N. sativa is to characterize the components that may 
have anti-cancer effects. In our study, we use TQ as a known compound standard to 
detect the peaks in the chromatogram that will help to indicate whether the active 
compound from N. sativa is a known compound or an unknown compound. The results 
showed that (ethanol extract, 40% ethanol fraction, and 60% ethanol fraction) have 
unknown compounds and a high level of TQ. Other extracts (aqueous extract, 20% 
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ethanol fraction, 80% ethanol fraction) have also unknown compounds but a low level of 
TQ.
Lastly, from our results we suggested that the anti-cancer activity of N. sativa is 
not only due to TQ, but there may be other anti-cancer agents which need to be further 
investigated in the future. The water extract which does not contain TQ also has anti-
proliferation activity suggesting other components are involved in regulating growth of 
cell culture.
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4.4 Conclusion
For many years, N. sativa is has been one of the well-known natural products that 
has been used ability to prevent many diseases as well as cancer.
In our study, we found that the 70% ethanol extract of N. sativa was shown to 
have cytotoxic effects on different types of malignant (B16-BL6, T98G) and three non-
malignant (293T, HBL 100, HSG) cell lines. However, the aqueous extract of N. sativa
was able to reduce the cell viability only of malignant cell lines. The available data in this 
study showed that the ethanol extract of N. sativa has cytotoxic activity against murine 
melanoma B16-BL6 cells by inducing apoptosis. The results from Acridine 
Orange/Ethidium Bromide staining assay, TUNEL assay, and caspase activity assay led 
us to conclude that the mechanism of death for B16-BL6 cells in response to the ethanol 
extract of N. sativa treatment was cellular apoptosis. In the future, before the 
development of a promising anti-cancer drug for cancer treatment from N. sativa, extra 
research will be required to identify and characterize the unknown components of N. 
sativa.
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Appendix
Morphological changes in T98G cells exposed to various concentrations of 
N. sativa with ethanolic extract or aqueous extract for 72 h.
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Morphological changes in HSG cells exposed to various concentrations of 
N. sativa with ethanolic extract or aqueous extract for 72 h.
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Morphological changes in HBL 100 cells exposed to various concentrations 
of N. sativa with ethanolic extract or aqueous extract for 72 h.
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